NEW YORK, April 17 – Athersys, which markets its Random Activation of Gene Expression technology for correlation of protein function and gene structure, withdrew its proposed $115 initial public offering in a filing with the Securities and Exchange Commission Tuesday. 

Athersys said it was canceling the IPO due to market conditions. But the Cleveland-based company said it might still sell shares in a private offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.